We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Scientists Prepare Disposable Lab-on-a-Chip for Diagnosis at POC

By LabMedica International staff writers
Posted on 01 Oct 2008
Low-cost, disposable cartridges would allow doctors to perform diagnostic tests at the point-of-care and speed up diagnosis and treatment.

European scientists are rapidly approaching their goal of producing a polymer-based device the size of a credit card that would be able to control the movement of biologic fluids, detect the presence of specific proteins, for example early signs of cancer, and analyze the results.

Scientists from Surface Enhanced Micro Optical Fluidic Systems, a consortium of multidisciplinary expertise divided among eight partners and five European countries, are working towards their goal of low cost disposable cartridges capable of quickly and accurately performing complex medical diagnostic tests. More...


The SEMOFS scientists reported that it has made the greatest progress in two areas--microfluidics and plasmonics. Microfluidics includes techniques for controlling the movement of minute quantities of fluids. The SEMOFS card moves blood, serum, and other fluids through channels slightly wider than a human hair. Once the biologic sample and the fluids necessary to process it have interacted in the proper sequence, the device uses plasmonics to determine if proteins from the sample have bonded to the detecting surfaces inside the card.

The scientists plan to pack everything, light sources and detector, waveguides, and the microfluidic system, into one polymer-based card. The electronics that will read the cards and display the results will be a separate unit. "We are targeting state-of-the-art sensitivities or better,” stated Jerôme Gavillet, the dissemination coordinator of SEMOFS, "in a system that could be available anywhere for less than EUR 50.”

Related Links:
SEMOFS



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.